Provided by Tiger Trade Technology Pte. Ltd.

Merck

144.20
-1.2475-0.86%
Volume:1.12M
Turnover:161.18M
Market Cap:355.77B
PE:113.29
High:145.93
Open:145.80
Low:143.50
Close:145.45
52wk High:156.92
52wk Low:82.01
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.80
T/O Rate:0.05%
Dividend:3.32
Dividend Rate:2.30%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.48
PE(LYR):19.81

Loading ...

Formycon Shares Jump After FDA Accepts Application for Keytruda Biosimilar

Dow Jones
·
3 hours ago

Merck Names Cressey Managing Partner Paul Diaz to Board Effective Nov. 1, 2026

Reuters
·
3 hours ago

Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.j., USA Board of Directors

THOMSON REUTERS
·
3 hours ago

Merck Presents First Phase 3 INTerpath-001 Data on Intismeran Plus Keytruda in Resected Melanoma at ESMO 2026

Reuters
·
3 hours ago

Merck Showcases First-Time Pivotal Phase 3 Results from Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at Esmo 2026

THOMSON REUTERS
·
3 hours ago

Merck & Co - Sac-TMT Phase 3 Trial Shows Improved Survival in Endometrial Cancer

THOMSON REUTERS
·
3 hours ago

Zydus-Formycon's Marketing Filing for Copycat Keytruda Submitted in North America

MT Newswires Live
·
8 hours ago

Merck's Recent Commentary Signals 'Modest' 2027 Growth, RBC Says

MT Newswires Live
·
Yesterday

Merck Price Target Cut to $145.00/Share from $150.00 by RBC Capital

Dow Jones
·
Yesterday

Merck & Company (MRK) Gets a Buy from Leerink Partners

TIPRANKS
·
Yesterday

Street View: Merck Eye Disease Drug Matches Roche's Therapy in Study, Analysts Cautious

Reuters
·
Yesterday

Citigroup Adjusts Price Target on Merck & Co. to $145 From $125

MT Newswires Live
·
Yesterday

Merck & Co Inc : RBC Cuts Target Price to $145 from $150

THOMSON REUTERS
·
Yesterday

Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Yesterday

Merck announces one-year results from Phase 2b/3 Brunello trial

TIPRANKS
·
Yesterday

Merck Says Remigromig Meets Primary Endpoint in Brunello Diabetic Macular Edema Trial at One Year

Reuters
·
Oct 11

Merck Presents One-Year Results from the Pivotal Phase 2B/3 Brunello Study Evaluating Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at Aao 2026

THOMSON REUTERS
·
Oct 11

Merck & Co - Remigromig Demonstrates Non-Inferior Visual Acuity Versus Ranibizumab at One Year in Dme

THOMSON REUTERS
·
Oct 11

Movement Alert|Merck Rises 3.02% in Regular Trading, EU Injunction Against Keytruda SC Seen Benefiting Halozyme

Market Focus
·
Oct 10

Sector Update: Healthcare

MT Newswires Live
·
Oct 10